Anxiety Disorders in the 21st Century: Status, Challenges, Opportunities, and Comorbidity With Depre

---

Implications of an SSRI Generic Step Therapy Pharmacy Benefit Design: An Economic Model in Anxiety Disorders

Patt Ellen Panzer, MD, MPH;Timothy S. Regan, BPharm, RPh, CPh;Evelyn Chiao, PharmD;Matthew W. Sarnes, PharmD

October 20th 2005

ArticleSUPPLEMENT CONTENT

---

Adherence to Paroxetine CR Compared With Paroxetine IR in a Medicare-eligible Population With Anxiety Disorders

Matthew S. Keene, MD;Michael T. Eaddy, PharmD, PhD;Winnie W. Nelson, PharmD, MS;Matthew W. Sarnes, PharmD

October 20th 2005

ArticleSUPPLEMENT CONTENT

---

Differences in Total Medical Costs Across the SSRIs for the Treatment of Depression and Anxiety

David V. Sheehan, MD, MBA;Michael T. Eaddy, PharmD, PhD;Manan B. Shah, PharmD, PhD;Robert P. Mauch, Jr, PharmD, PhD

October 20th 2005

ArticleSUPPLEMENT CONTENT

---

Participating Faculty

October 20th 2005

ArticleSUPPLEMENT CONTENT

---

Anxiety Disorders in the 21st Century: Status, Challenges, Opportunities, and Comorbidity With Depression

C. Lindsay DeVane, PharmD;Evelyn Chiao, PharmD;Meg Franklin, PharmD;Eric J. Kruep, PharmD, MS

October 20th 2005

ArticleSUPPLEMENT CONTENT